D
goxin and diuretics were once the cornerstones of
therapy for patients with chronic heart failure. During
the past 2 decades, an increasing number of therapeutic
options for the treatment of symptomatic heart failure has
emerged. Demonstrated benefit of these therapies has led to
parallel growth of practice guidelines and performance mea-
sures. As a result, physicians caring for patients with heart
failure face the increasing challenge of introducing and
titrating multiple medications to achieve the perceived benefit
promised by clinical trials while adhering to guideline-driven
treatment algorithms.

The role of digoxin in the treatment of heart failure is long
and storied, with the Digitalis Investigation Group (DIG) trial
a relatively recent addition.1 Currently, the addition of
digoxin for the treatment of stage C heart failure is a 2B (level
of evidence B) recommendation.2 The DIG trial itself is still
undergoing reinterpretation, particularly for subgroups de-

dined by gender or clinical severity. However, the patients in
the DIG trial may no longer reflect the heart failure popula-
tion today, which has been reshaped by β-blockers, aldoste-
rone antagonists, and devices to resynchronize contraction
and prevent sudden death. Furthermore, the serum digoxin
concentrations of many of the patients in the DIG study

References
1. The effect of digoxin on mortality and morbidity in patients with heart
525–533.
PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, C. SS, Jr,
Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF,
Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American
College of Cardiology; American Heart Association Task Force on
Practice Guidelines; American College of Chest Physicians; Interna-
tional Society for Heart and Lung Transplantation; Heart Rhythm Society.
ACC/AHA 2005 guideline update for the diagnosis and management of
chronic heart failure in the adult: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (writing committee to update the 2001 guidelines for the
evaluation and management of heart failure)—developed in collaboration
with the American College of Chest Physicians and the International
Society for Heart and Lung Transplantation: endorsed by the Heart
MW. Effects of discontinuation of digoxin versus continuation at low
serum digoxin concentrations in chronic heart failure. Am J Cardiol.
2007;100:280–284.
4. Adams KF Jr, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA,
Young JB. Clinical benefits of low serum digoxin concentrations in heart

KEY WORDS: heart failure ▪ digoxin ▪ treatment
EDITOR'S NOTE

Challenges for the Basis of Practice will be a regular feature of Circulation: Heart Failure (see Stevenson LW. Challenges for the basis of practice in heart failure. Circ Heart Fail. 2008;1:81–83). It is designed to provide a forum for presentation and discussion of decisions arising commonly during the care of individual patients. The essence of “practice” in the context of medicine is best defined by its earliest meaning, “actual application of a plan or method, as opposed to the theories relating to it,” from the Greek work “praktikos,” meaning “concerned with action” (see Compact Oxford English Dictionary. Oxford, United Kingdom: Oxford University Press; 2005). Each day, most of the questions that must be answered in real time are unanswered by clinical trials, and many are unanswered even by those guidelines with level of evidence C, on which expert consensus has been reached from clinical experience without a randomized basis of evidence.

A Challenge to Practice topic can be submitted, in 500 words or less, by up to 5 clinicians, who can include physicians and/or nurses and will be cited as authors. After selection of the topic, a recognized expert consultant will be invited to review his or her own practical approach to the question.

The first topic selected was the use of digoxin in contemporary practice, as well-summarized by Drs May and Diaz from Portland, Me. The challenge was accepted by Dr Gary Francis, widely recognized as a master clinician as well as a scientist contributing profoundly to our understanding of the pathophysiology of heart failure.

Readers are invited to submit brief responses after publication of the question and expert review. These may describe personal clinical experience or practical lessons gleaned from published literature and should be identified as “Challenge Response” when submitted. Representative views will be selected for publication in excerpt form in subsequent issues. Although many controversies cannot be fully resolved with current experience, we are confident that this forum will stimulate observation and provide reassurance that we do not practice alone, but within a dedicated community.
The Role of Digoxin in the Treatment of Heart Failure
Christopher W. May and Marco N. Diaz

Circ Heart Fail. 2008;1:206-207
doi: 10.1161/CIRCHEARTFAILURE.108.811869
Circulation: Heart Failure is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/1/3/206